相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman et al.
AGING-US (2011)
The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir
Filippo Canducci et al.
ANTIVIRAL RESEARCH (2011)
The expanding relevance of nuclear mTOR in carcinogenesis
Jung H. Back et al.
CELL CYCLE (2011)
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells
Marco Donia et al.
CELL CYCLE (2011)
Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro
Rachel M. A. Barrett et al.
CELL CYCLE (2011)
High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
Paige Yellen et al.
CELL CYCLE (2011)
The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells
Kathrin Zitzmann et al.
ENDOCRINE-RELATED CANCER (2011)
Cytotoxic and Immune-Sensitizing Properties of Nitric Oxide-Modified Saquinavir in iNOS-Positive Human Melanoma Cells
Sanja Mijatovic et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells
Eun-Sil Sung et al.
APOPTOSIS (2010)
Tyrosine phosphorylation and CD95 A FAScinating switch
Ignacio Sancho-Martinez et al.
CELL CYCLE (2009)
The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt
Danijela Maksimovic-Ivanic et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Anti-HIV drugs for cancer therapeutics: back to the future?
Warren A. Chow et al.
LANCET ONCOLOGY (2009)
TRAIL death receptors as tumor suppressors and drug targets
Niklas Finnberg et al.
CELL CYCLE (2008)
Targeting prostate cancer based on signal transduction and cell cycle pathways
John T. Lee et al.
CELL CYCLE (2008)
TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
Andrew Thorburn et al.
DRUG RESISTANCE UPDATES (2008)
Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells
Catherine Wilson et al.
MOLECULAR CANCER THERAPEUTICS (2008)
FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells
A. N. Cornforth et al.
ONCOGENE (2008)
Targeting death-inducing receptors in cancer therapy
K. Takeda et al.
ONCOGENE (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
SAHA-sensitized prostate cancer cells to TNFα-related apoptosis-inducing ligand (TRAIL):: Mechanisms leading to synergistic apoptosis
Vijavabaskar Lakshmikanthan et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme
Amith Panner et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells
A Panner et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines
CH Tang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth
C Sgadari et al.
LANCET ONCOLOGY (2003)
Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP
KI Jeon et al.
FEBS LETTERS (2003)
Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
A Nesterov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)
H Wajant et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: Role of La autoantigen in XIAP translation
M Holcik et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
